NOV 20, 2013 10:00 AM PST

Navigating the Evolving Molecular Diagnostic Reimbursement Landscape to Optimize Coverage and Payment and Identify Opportunities

Speakers
  • Vice President, Client Services, Quorum Consulting
    Biography
      Nicole Littmann is a leading expert in development and implementation of reimbursement strategy for innovative medical technologies, with over 15 years of experience in health care and public policy, 10 of those years in reimbursement consulting. Ms. Littmann has worked across various diagnostic and therapeutic areas, including molecular pathology, oncology, cardiology/cardiac surgery, and spine/orthopedics. From the time CMS implemented unique payment pathways for new technologies, she has been at the forefront of securing carve-out payment for her clients' technologies under Medicare. She has well-established relationships with payer decision-makers at both coverage and payment policy levels, as well in-depth technical and procedural knowledge of the AMA and CMS processes to secure CPT and HCPCS codes for these technologies. Ms. Littmann has helped manufacturers, providers, and patients navigate the health care system for access to medical innovation through clinical trial coverage and reimbursement, running efficient coding and billing hotlines, and implementing customized, effective appeals programs and patient assistance programs.

    Abstract:
    2013 has proven to be a year of paradigmatic shifts in molecular diagnostics reimbursement policy. In this session, we will review and analyze these key policy and payment developments and discuss how your company can optimize the adoption of novel molecular diagnostic tests by developing strategies that consider the dynamic and changing reimbursement landscape. The key learning objectives from this presentation are as follows:

    - Understand the current coding landscape and potential payment rates for these lab services
    - Learn the implications for the new McKesson/American Medical Association partnership
    - Be aware of coding development for future next-generation sequencing technology
    - Learn about the different levels of evidence that drive coverage for diagnostic tests

    Show Resources
    You May Also Like
    AUG 16, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 16, 2018 08:00 AM PDT
    DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    SEP 12, 2017 08:00 AM PDT
    SEP 12, 2017 08:00 AM PDT
    DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
    NOV 15, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    Loading Comments...